NASDAQ: HKPDCellyan Biotechnology Co Ltd Stock
$0.45+0.03 (+7.14%)
Updated Jun 15, 2026
HKPD Price
$0.45
Fair Value Price
$1.00
Market Cap
$4.90M
52 Week Low
$0.32
52 Week High
$2.58
P/E
-6.18x
P/B
0.95x
P/S
0.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.36M
Earnings
-$701.88k
Gross Margin
8.8%
Operating Margin
-4.03%
Profit Margin
-4.3%
Debt to Equity
0.87
Operating Cash Flow
-$428k
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HKPD Overview
Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HKPD's potential to beat the market
- HKPD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
HKPD
RankedUnranked of 4
RankedUnranked of 4
Be the first to know about important HKPD news, forecast changes, insider trades & much more!
HKPD News
Overview
Due Diligence Score
–
Industry Average (19)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HKPD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HKPD ($0.45) is undervalued by 55.54% relative to our estimate of its Fair Value price of $1.00 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HKPD ($0.45) is significantly undervalued by 55.54% relative to our estimate of its Fair Value price of $1.00 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HKPD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HKPD due diligence checks available for Premium users.
Valuation
HKPD fair value
Fair Value of HKPD stock based on Discounted Cash Flow (DCF)
Price
$0.45
Fair Value
$1.00
Undervalued by
55.04%
HKPD ($0.45) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HKPD ($0.45) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HKPD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HKPD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.18x
Industry
-3.72x
Market
14.3x
HKPD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.95x
Industry
44.18x
HKPD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HKPD's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
HKPD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HKPD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.6M
Liabilities
$4.5M
Debt to equity
0.87
HKPD's short-term assets ($8.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HKPD's short-term assets ($8.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HKPD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
HKPD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HKPD vs Pharmaceutical Retailer Stocks
Cellyan Biotechnology Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.